Skip to main content

Diabetes Could Speed Progression of Blood Cancer Myeloma

Medically reviewed by Drugs.com.

By Cara Murez HealthDay Reporter

MONDAY, Oct. 2, 2023 -- Diabetes may accelerate the growth of a blood cancer known as multiple myeloma, affecting overall survival, according to a new study.

The research, published Sept. 29 in the journal Blood Advances, also underscores differences in survival outcomes for Black patients versus white patients with both conditions. In this study group, diabetes affected survival rates in white patients, but not in Black patients.

“We knew from prior studies that patients with multiple myeloma and diabetes have lower survival rates, but what we did not know is how these outcomes differ between races,” said study author Dr. Urvi Shah, multiple myeloma specialist at Memorial Sloan Kettering Cancer Center in New York City.

“Diabetes is much more common in Black individuals versus white individuals, and we wanted to understand whether this difference may play a role in health outcomes among patients with both conditions," she said in a journal news release.

Multiple myeloma is cancer of plasma cells in the bone marrow. It is the second-most common blood cancer in the United States. Among Black adults, it is the most common.

Diabetes affects about 13% of the U.S. population, and the rate is on the rise, according to the U.S. Centers for Disease Control and Prevention.

For the study, researchers examined electronic health records of more than 5,300 patients with multiple myeloma who were treated at two academic medical centers.

Fifteen percent had a diabetes diagnosis, including 12% of white patients and 25% of Black patients.

Patients with myeloma who also had diabetes had poorer survival rates than those without diabetes.

When researchers broke this down by race, white patients with myeloma and diabetes had lower survival rates than those without diabetes. They didn't see this in Black patients, however.

“What we did not expect to see here was that diabetes was actually associated with worse survival outcomes among white individuals with myeloma, but not Black individuals,” Shah said.

Generally, a person’s risk for diabetes increases with age, Shah said. Overall survival declines with age.

However, in this study, diabetes was 50% more prevalent among Black patients between 45 and 60 years old than in white patients over 60.

Researchers said younger patients may tolerate multiple myeloma treatments better than older individuals, which could explain some of the racial differences they observed in survival outcomes.

Researchers also investigated tumor growth in genetically engineered mouse models. They found that multiple myeloma tumors grew faster in non-obese diabetic mice than in non-diabetic controls.

An insulin-related signal was overactivated in the diabetic mice, researchers found. Higher insulin levels associated with diabetes may speed up cancer growth.

“In my own practice, I work with many patients with both multiple myeloma and diabetes. And usually treating multiple myeloma involves many rounds of chemotherapy,” Shah said. “But this study suggests that we may also improve patient outcomes further by treating diabetes at the same time.”

In the future, Shah hopes to identify therapies that stop development of multiple myeloma as well as the overactive insulin signaling pathway in patients with multiple myeloma and diabetes.

She is also investigating whether making changes in one's microbiome and diet may improve cancer outcomes.

Sources

  • Blood Advances, news release, Sept. 29, 2023

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted October 2023

Read this next

Ozempic Lowers Odds for Death, Illness in People With Kidney Disease and Type 2 Diabetes

FRIDAY, May 24, 2024 -- Ozempic provides a wide variety of health benefits for people with kidney disease and type 2 diabetes, a major clinical trial has found. The drug...

Costs, Side Effects Drive Folks to Quit New Weight-Loss Meds

THURSDAY, May 23, 2024 -- Three months after starting one of the new GLP-1 weight-loss drugs, more than a quarter of patients have already quit the medications, and by a year from...

Use of GLP-1 Meds Have Risen 7-Fold Among Young Americans

WEDNESDAY, May 22, 2024 -- The number of American teens and young adults who've been prescribed one of the new GLP-1 weight-loss drugs soared nearly seven-fold between 2020 and...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.